S&P 500   4,509.15 (-1.48%)
DOW   34,358.06 (-0.81%)
QQQ   380.19 (-2.49%)
AAPL   160.14 (-2.21%)
MSFT   320.00 (-2.88%)
FB   304.22 (-1.99%)
GOOGL   2,817.11 (-1.48%)
AMZN   3,357.83 (-2.31%)
TSLA   1,013.85 (-6.52%)
NVDA   303.15 (-5.64%)
BABA   112.32 (-7.93%)
NIO   31.87 (-11.96%)
CGC   9.92 (-4.25%)
AMD   141.88 (-5.84%)
GE   91.95 (-3.44%)
MU   80.99 (-2.28%)
T   23.40 (+1.52%)
F   19.00 (-4.38%)
DIS   144.58 (-1.78%)
PFE   54.12 (+2.04%)
AMC   26.17 (-13.57%)
ACB   5.75 (-6.35%)
BA   195.90 (-3.20%)
S&P 500   4,509.15 (-1.48%)
DOW   34,358.06 (-0.81%)
QQQ   380.19 (-2.49%)
AAPL   160.14 (-2.21%)
MSFT   320.00 (-2.88%)
FB   304.22 (-1.99%)
GOOGL   2,817.11 (-1.48%)
AMZN   3,357.83 (-2.31%)
TSLA   1,013.85 (-6.52%)
NVDA   303.15 (-5.64%)
BABA   112.32 (-7.93%)
NIO   31.87 (-11.96%)
CGC   9.92 (-4.25%)
AMD   141.88 (-5.84%)
GE   91.95 (-3.44%)
MU   80.99 (-2.28%)
T   23.40 (+1.52%)
F   19.00 (-4.38%)
DIS   144.58 (-1.78%)
PFE   54.12 (+2.04%)
AMC   26.17 (-13.57%)
ACB   5.75 (-6.35%)
BA   195.90 (-3.20%)
S&P 500   4,509.15 (-1.48%)
DOW   34,358.06 (-0.81%)
QQQ   380.19 (-2.49%)
AAPL   160.14 (-2.21%)
MSFT   320.00 (-2.88%)
FB   304.22 (-1.99%)
GOOGL   2,817.11 (-1.48%)
AMZN   3,357.83 (-2.31%)
TSLA   1,013.85 (-6.52%)
NVDA   303.15 (-5.64%)
BABA   112.32 (-7.93%)
NIO   31.87 (-11.96%)
CGC   9.92 (-4.25%)
AMD   141.88 (-5.84%)
GE   91.95 (-3.44%)
MU   80.99 (-2.28%)
T   23.40 (+1.52%)
F   19.00 (-4.38%)
DIS   144.58 (-1.78%)
PFE   54.12 (+2.04%)
AMC   26.17 (-13.57%)
ACB   5.75 (-6.35%)
BA   195.90 (-3.20%)
S&P 500   4,509.15 (-1.48%)
DOW   34,358.06 (-0.81%)
QQQ   380.19 (-2.49%)
AAPL   160.14 (-2.21%)
MSFT   320.00 (-2.88%)
FB   304.22 (-1.99%)
GOOGL   2,817.11 (-1.48%)
AMZN   3,357.83 (-2.31%)
TSLA   1,013.85 (-6.52%)
NVDA   303.15 (-5.64%)
BABA   112.32 (-7.93%)
NIO   31.87 (-11.96%)
CGC   9.92 (-4.25%)
AMD   141.88 (-5.84%)
GE   91.95 (-3.44%)
MU   80.99 (-2.28%)
T   23.40 (+1.52%)
F   19.00 (-4.38%)
DIS   144.58 (-1.78%)
PFE   54.12 (+2.04%)
AMC   26.17 (-13.57%)
ACB   5.75 (-6.35%)
BA   195.90 (-3.20%)
NASDAQ:BCAB

BioAtla Stock Forecast, Price & News

$22.60
-0.39 (-1.70%)
(As of 12/3/2021 02:37 PM ET)
Add
Compare
Today's Range
$21.65
$23.30
50-Day Range
$21.80
$31.80
52-Week Range
$21.38
$76.63
Volume
13,715 shs
Average Volume
228,671 shs
Market Capitalization
$832.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive BCAB News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.


BioAtla logo

About BioAtla

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.

Headlines

BioAtla (NASDAQ:BCAB) Trading Down 3.2% After Insider Selling
December 1, 2021 |  americanbankingnews.com
BioAtla, Inc. (NASDAQ:BCAB) President Sells $11,278.90 in Stock
November 30, 2021 |  americanbankingnews.com
BioAtla, Inc. (NASDAQ:BCAB) CFO Richard A. Waldron Sells 3,626 Shares
November 30, 2021 |  americanbankingnews.com
BioAtla, Inc. (NASDAQ:BCAB) CFO Sells $97,913.19 in Stock
November 30, 2021 |  americanbankingnews.com
BioAtla (NASDAQ:BCAB) Hits New 1-Year Low at $23.23
November 29, 2021 |  americanbankingnews.com
BioAtla (NASDAQ:BCAB) Shares Gap Down to $25.82
November 24, 2021 |  americanbankingnews.com
BioAtla (NASDAQ:BCAB) Sets New 52-Week Low at $24.56
November 23, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCAB
Phone
N/A
Fax
N/A
Employees
36
Year Founded
N/A

Sales & Book Value

Annual Sales
$430 thousand
Book Value
$6.24 per share

Profitability

Net Income
$-35.85 million
Pretax Margin
-35,362.80%

Debt

Price-To-Earnings

Miscellaneous

Free Float
23,759,000
Market Cap
$832.49 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/21/2022

MarketRank

Overall MarketRank

2.53 out of 5 stars

Medical Sector

106th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

12th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












BioAtla (NASDAQ:BCAB) Frequently Asked Questions

Is BioAtla a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioAtla stock.
View analyst ratings for BioAtla
or view top-rated stocks.

When is BioAtla's next earnings date?

BioAtla is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for BioAtla
.

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) released its earnings results on Monday, November, 15th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.04.
View BioAtla's earnings history
.

What price target have analysts set for BCAB?

5 analysts have issued 1-year price targets for BioAtla's shares. Their forecasts range from $49.00 to $87.00. On average, they anticipate BioAtla's share price to reach $65.20 in the next year. This suggests a possible upside of 188.5% from the stock's current price.
View analysts' price targets for BioAtla
or view top-rated stocks among Wall Street analysts.

Who are BioAtla's key executives?

BioAtla's management team includes the following people:
  • Dr. Jay M. Short, Co-Founder, CEO & Chairman (Age 63, Pay $1.06M)
  • Mr. Scott Andrew Smith, Pres & Director (Age 59, Pay $824.51k) (LinkedIn Profile)
  • Ms. Carolyn Anderson Short, Co-Founder, Exec. VP and Chief of Intellectual Property & Strategy (Age 56, Pay $859.2k)
  • Mr. Richard A. Waldron, Chief Financial Officer (Age 67)
  • Mr. Philippe Martin, Chief Clinical Devel. & Operations (Age 45)
  • Lisa M. Pelton, Accounting Mang.
  • Ms. Susie Melody, VP of HR
  • Dr. Eric L. Sievers, Chief Medical Officer (Age 57) (LinkedIn Profile)
  • Mr. Christian Vasquez, VP of Fin., Corp. Controller & Sec. (Age 46)

When did BioAtla IPO?

(BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO.

What is BioAtla's stock symbol?

BioAtla trades on the NASDAQ under the ticker symbol "BCAB."

Who are BioAtla's major shareholders?

BioAtla's stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (6.78%), Janus Henderson Group PLC (5.12%), BlackRock Inc. (3.76%), Great Point Partners LLC (2.50%), Massachusetts Financial Services Co. MA (1.45%) and Deerfield Management Company L.P. Series C (1.37%). Company insiders that own BioAtla stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron and Scott Andrew Smith.
View institutional ownership trends for BioAtla
.

Which institutional investors are selling BioAtla stock?

BCAB stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Deutsche Bank AG, Wellington Management Group LLP, Geode Capital Management LLC, Citigroup Inc., New York State Common Retirement Fund, and Alliancebernstein L.P.. Company insiders that have sold BioAtla company stock in the last year include Christian Vasquez, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, and Scott Andrew Smith.
View insider buying and selling activity for BioAtla
or view top insider-selling stocks.

Which institutional investors are buying BioAtla stock?

BCAB stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Janus Henderson Group PLC, Suvretta Capital Management LLC, Candriam Luxembourg S.C.A., Morgan Stanley, Deerfield Management Company L.P. Series C, Sphera Funds Management LTD., and BlackRock Inc.. Company insiders that have bought BioAtla stock in the last two years include Cormorant Asset Management, Lp, and Guy Levy.
View insider buying and selling activity for BioAtla
or or view top insider-buying stocks.

How do I buy shares of BioAtla?

Shares of BCAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioAtla's stock price today?

One share of BCAB stock can currently be purchased for approximately $22.60.

How much money does BioAtla make?

BioAtla has a market capitalization of $832.49 million and generates $430 thousand in revenue each year.

How many employees does BioAtla have?

BioAtla employs 36 workers across the globe.

What is BioAtla's official website?

The official website for BioAtla is www.bioatla.com.

How can I contact BioAtla?

The company can be reached via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.